BioSyent Inc. (OTCMKTS:BIOYF – Get Free Report) saw a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 400 shares, a decrease of 69.2% from the October 31st total of 1,300 shares. Based on an average daily volume of 4,000 shares, the short-interest ratio is currently 0.1 days.
BioSyent Stock Performance
BioSyent stock remained flat at $8.05 during mid-day trading on Thursday. The company had a trading volume of 100 shares, compared to its average volume of 2,237. The business has a 50 day simple moving average of $8.03 and a two-hundred day simple moving average of $7.54. BioSyent has a 1-year low of $5.93 and a 1-year high of $8.90.
BioSyent Cuts Dividend
The firm also recently disclosed a dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be issued a dividend of $0.0322 per share. This represents a yield of 1.6%. The ex-dividend date is Friday, November 29th.
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
See Also
- Five stocks we like better than BioSyent
- Health Care Stocks Explained: Why You Might Want to Invest
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Top Stocks Investing in 5G Technology
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Top Biotech Stocks: Exploring Innovation Opportunities
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.